

产品名称: 5-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline
 产品别名: LDN-212854

生物活性:

Description	<p>LDN-212854 is a novel BMP inhibitor that exhibits substantially greater selectivity for BMP versus the TGF-β type I receptors; possesses a bias towards ALK2(IC₅₀=1.3 nM) versus ALK1 and ALK3 compared to other inhibitors. IC₅₀ value: 1.3 nM [1] Target: ALK2 In vitro, LDN-212854 exhibits some selectivity for ALK2 in preference to other BMP type I receptors, ALK1 and ALK3, which may permit the interrogation of ALK2-mediated signaling, transcriptional activity and function. LDN-212854 potently inhibits heterotopic ossification in an inducible transgenic mutant ALK2 mouse model of fibrodysplasia ossificans progressiva.</p>																		
Solvent&Solubility	<p>In Vitro:</p> <p>DMSO : ≥ 30 mg/mL (73.80 mM)</p> <p>H₂O : < 0.1 mg/mL (insoluble)</p> <p>* "≥" means soluble, but saturation unknown.</p>																		
	<table><tr><th rowspan="2">Preparing Stock Solutions</th><th><div>SolventMassConcentration</div></th><th>1 mg</th><th>5 mg</th><th>10 mg</th></tr><tr><th>1 mM</th><td>2.4601 mL</td><td>12.3007 mL</td><td>24.6015 mL</td></tr><tr><th rowspan="2"></th><th>5 mM</th><td>0.4920 mL</td><td>2.4601 mL</td><td>4.9203 mL</td></tr><tr><th>10 mM</th><td>0.2460 mL</td><td>1.2301 mL</td><td>2.4601 mL</td></tr></table>	Preparing Stock Solutions	<div>SolventMassConcentration</div>	1 mg	5 mg	10 mg	1 mM	2.4601 mL	12.3007 mL	24.6015 mL		5 mM	0.4920 mL	2.4601 mL	4.9203 mL	10 mM	0.2460 mL	1.2301 mL	2.4601 mL
	Preparing Stock Solutions		<div>SolventMassConcentration</div>	1 mg	5 mg	10 mg													
		1 mM	2.4601 mL	12.3007 mL	24.6015 mL														
		5 mM	0.4920 mL	2.4601 mL	4.9203 mL														
10 mM		0.2460 mL	1.2301 mL	2.4601 mL															
<p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。</p> <p>储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。</p> <p>In Vivo:</p> <p>请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：</p> <p>——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶</p> <p>1.请依序添加每种溶剂： 10% DMSO→40% PEG300 →5% Tween-80 → 45% saline Solubility: 2.5 mg/mL (6.15 mM); Suspended solution; Need ultrasonic 此方案可获得 2.5 mg/mL (6.15 mM)的均匀悬浊液，悬浊液可用于口服和腹腔注射。</p> <p>以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入 50 μL Tween-80，混合均匀；然后继续加入 450 μL 生理盐水定容至 1 mL。</p> <p>2.请依序添加每种溶剂： 10% DMSO→ 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (6.15 mM); Suspended solution; Need ultrasonic 此方案可获得 2.5 mg/mL (6.15 mM)的均匀悬浊液，悬浊液可用于口服和腹腔注射。</p> <p>以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。</p>																			
References	<p>[1]. Mohedas AH, et al. Development of an ALK2-biased BMP type I receptor kinase inhibitor. ACS Chem Biol. 2013;8(6):1291-302.</p>																		